解读神经元缺陷和人类大脑器官中的蛋白质概况变化,来自肌酸载体缺乏症患者
Léa Broca-Brisson1, Rania Harati2,3, Clémence Disdier4
1Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, Gif sur Yvette, France.
eLife
|October 13, 2023
概括
肌酸载体缺乏症 (CTD) 是一种影响大脑发育的X相关疾病. 人类大脑的器官显示肌酸摄取受损和神经发生变化,这表明恢复肌酸水平具有潜在的治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 发展生物学 发展生物学
背景情况:
- 肌酸转运体缺乏症 (CTD) 是一种X系遗传疾病.
- 在SLC6A8基因突变损害了大脑中的肌酸吸收.
- CTD导致智力障碍,发育迟缓和发作.
研究的目的:
- 使用人类大脑器官来研究CTD的病理生理学.
- 分析受损肌酸摄取对神经发生和蛋白质表达的影响.
- 评估恢复肌酸水平作为治疗策略的潜力.
主要方法:
- 从CTD患者和健康对照的诱导多能干细胞生成人类大脑器官.
- 评估肌酸吸收和关键神经发育标志物的表达 (SOX2,PAX6,GSK3β).
- 枪支蛋白质组学和生物信息学分析以确定蛋白质丰度的变化.
主要成果:
- 从CTD衍生的有机体表现出较低的肌酸摄入量和较低的SOX2/PAX6表达.
- 在CTD有机体中观察到GSK3β的上调,这表明神经发生变化.
- 蛋白质组分析确定了与智力障碍,和自闭症相关的蛋白质变化.
- 恢复SLC6A8功能使肌酸摄取和关键蛋白质表达正常化.
结论:
- 人类大脑有机体可以作为研究CTD的宝贵模型.
- 肌酸运输障碍显著影响大脑发育和神经发生.
- 恢复肌酸水平对CTD患者具有治疗潜力.
相关概念视频
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...


